VANCOUVER, British Columbia -- Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) announced that the Company has signed a second partner, Guangzhou Wondfo Biotech Co., Ltd. (Wondfo) in China to sell the Company鈥檚 diagnostic products, expanding its strategic presence in this important global market.
鈥淲e have already seen great success in China with our first partner, O&D Biotech Co., Ltd. China (O&D), selling our co-branded RAMP庐 cardiac pandora style beads products over the past few years,鈥?said S. Wayne Kay, Chief Executive Officer. 鈥淚n 2009, we recognized a significant portion of our revenues from sales in China. We are pleased to sign the Wondfo agreement and with representation by two strong partners in this region, we expect sales in China to continue to make an important contribution to our overall revenues.鈥?
"China is an exciting and growing market and our continued international market expansion is extremely important to our overall strategy. Wondfo will be selling private label cardiac products, while O&D sells co-branded RAMP庐 products on both the RAMP庐 and RAMP庐 200 Readers."
About Response Biomedical
Response Biomedical develops, manufactures and markets rapid on-site diagnostic tests for use with its RAMP庐 Platform for clinical and environmental applications. RAMP庐 represents a new paradigm in diagnostics that provides high sensitivity and reliable information in minutes. It is ideally suited to both point of care testing and laboratory use.
The RAMP庐 system consists of a Reader and single-use disposable test cartridges, and has the potential to be adapted to more than 250 medical and non-medical tests currently performed in laboratories. RAMP庐 clinical tests are commercially available for the early detection of heart attack, congestive heart failure, influenza and RSV through our commercial partners, Roche and 3M Health Care respectively and the Company.
In the non-clinical market, RAMP庐 Tests are currently provided for the environmental detection of West Nile Virus, and Biodefense applications including the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin. Several other product applications are under development.
Response has achieved CE Marking for its Reader and clinical tests and its Quality Management System is registered to ISO 13485: 2003 and ISO 9001: 2008.
Response Biomedical is a publicly-traded company listed on the TSX under the trading symbol "RBM"聽and quoted on the OTC Bulletin Board under the postcard printing symbol "RPBIF". For further information, please visit the Company's website at .
Statements contained in this press release relating to future results, events or developments, for example, statements containing the words "believes," "may," "could", "plans," "will," "estimate," "continue," "anticipates," "intends," "expects", 鈥済oal鈥?and similar expressions, are "forward-looking statements" or 鈥渇orward-looking information鈥?under applicable United States and Canadian securities laws. Forward-looking statements or information may involve, but are not limited to, comments with respect to our planned activities, business plan and strategies and their future implementation, and our expectations for our financi
Other articles:
http://www.boni8.com/Blog/View/?1445
http://www.noachspace.com/blog/view/id_53/title_deadly-weapons-in-hot-pink-are/
http://www.xxxp.cn/Blog/View/?1071
http://zaalt.net/blog.php?user=mywatches&blogentry_id=119
http://mywatches.sportblog.si/2010/02/04/charity-pamper-night/
